



# Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group

Meeting to commence at 9.30 am on Tuesday 15<sup>th</sup> September 2020  
(via Zoom)

## AGENDA

- |  | Enclosure                  |
|--|----------------------------|
| 1. Welcome and introduction  |                            |
| 2. Apologies   |                            |
| 3. Declarations of interest  |                            |
| 4. Minutes of the previous meeting   | 1/AWMSG/0920               |
| 5. Chairman's verbal report  |                            |
| 6. National Prescribing Indicators – Quarterly report to March 2020 - for information  | 2/AWMSG/0920               |
| 7. Royal College of Paediatrics and Child Health and Neonatal and Paediatrics Pharmacist Group position statement - Using Standardised Strengths of Unlicensed Liquid Medicines in Children – for acknowledgement  | 3/AWMSG/0920               |
| 9. Feedback from AWPAG Meeting held 10 <sup>th</sup> June 2020   | 4/AWMSG/0920               |
| 10. Appraisal 1: Limited submission (Ultra-Orphan) bedaquiline (Sirturo <sup>®</sup> ) for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adolescent patients (12 years to less than 18 years of age and weighing at least 30 kg) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability | 5/AWMSG/0920<br>Enclosures |
| <b>To protect commercial confidentiality the following appraisals will be held in private and all observers will be asked to leave the meeting</b>   |                            |
| 11. Appraisal 2: Full submission (Wales Patient Access Scheme) doravirine (Pifeltro <sup>®</sup> ) in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the NNRTI class  | 6/AWMSG/0920<br>Enclosures |
| 12. Appraisal 3: Limited submission (Wales Patient Access Scheme) doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo <sup>®</sup> ) for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir  | 7/AWMSG/0920<br>Enclosures |

**The outcome of the appraisals will be uploaded to the AWMSG website after the meeting. The applicant companies will have ten working days to accept the decision or lodge a request for a review which should be sent to the AWMSG Chair via AWTTTC. AWMSG's recommendation/s will be forwarded to Welsh Government for ratification following acceptance of the outcome by the applicant companies or after the ten day deadline has expired – whichever is sooner. Welsh Government will take into account the AWMSG recommendation when making the final decision on the availability of the medicine in NHS Wales.**

**Date of next meeting: Tuesday 13<sup>th</sup> October 2020 commencing 9.30 am**